Third misoprostol formulation receives WHO prequalification

27th April 2016

This month, misoprostol produced by Indian manufacturer (and Coalition member) ACME Formulation Pvt Ltd received WHO Prequalification, making this the third misoprostol formulation to do so.

Misoprostol is a uterotonic which is administered to mothers post-partum to stop excessive bleeding at birth, the leading cause of maternal mortality. An up-to-date list of WHO prequalified medicinal drugs can be found here.

Categories: Maternal Health Supplies Caucus, Power of Partnership